Nurix Therapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nurix Therapeutics, Inc. (Nasdaq: NRIX) on October 16, 2024, reporting events that occurred on October 15, 2024. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Anil Kapur as a director and member of the Development Advisory Committee, effective October 15, 2024. Mr. Kapur serves as a Class I director with a term expiring at the 2027 annual meeting of stockholders.
Compensation and Governance Details
- Cash Compensation: Mr. Kapur will receive a pro rata portion of the $50,000 annual director retainer and a pro rata portion of the $5,000 annual Development Advisory Committee retainer for the remainder of the fiscal year ending November 30, 2024.
- Initial Equity Award: A stock option to purchase 50,000 shares of common stock was granted on October 15, 2024. The exercise price equals the closing sale price on the grant date. The award vests monthly over three years, contingent on continued service.
- Annual Equity Award: Mr. Kapur is eligible for customary annual equity compensation, currently consisting of a stock option to purchase 25,000 shares, vesting on the earlier of the next annual meeting or one year from the grant date.
- Acceleration: Both the Initial Award and Annual Awards accelerate in full upon the consummation of a Corporate Transaction.
- Indemnification: The Company entered into its standard form of indemnification agreement with Mr. Kapur.
Investor Verification Checklist
- Verify the closing stock price on October 15, 2024, to determine the exercise price of the 50,000 share Initial Award.
- Review the Company's 2020 Equity Incentive Plan to understand the specific definition of a "Corporate Transaction" triggering award acceleration.
- Confirm the exact pro rata cash compensation amounts calculated for the period from October 15, 2024, to November 30, 2024.
- Check the press release (Exhibit 99.1) for additional biographical details on Anil Kapur's qualifications.